Tectonic Therapeutic, Inc. (TECX)

Market Cap	405.57M
Revenue (ttm)	n/a
Net Income (ttm)	-58.67M
Shares Out	18.67M
EPS (ttm)	-4.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	152,322
Open	21.46
Previous Close	21.55
Day's Range	20.86 - 21.83
52-Week Range	13.70 - 61.07
Beta	n/a
Analysts	Buy
Price Target	79.20 (+264.64%)
Earnings Date	Aug 13, 2025

About TECX

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPC...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: TECX
• Website: https://tectonictx.com

Financial Performance

Financial numbers in USD

Analyst Summary

According to 5 analysts, the average rating for TECX stock is "Buy." The 12-month stock price target is $79.2, which is an increase of 264.64% from the latest price.

Price Target

$79.2

(264.64% upside)

Analyst Consensus: Buy